武海涛①, 姬忠贺①, 张倩①, 彭开文①, 李雁①②. 洛铂联合多西他赛行肿瘤细胞减灭术加腹腔热灌注化疗治疗同时性胃癌腹膜癌*[J]. 中国肿瘤临床, 2016, 43(4): 146-151. DOI: 10.3969/j.issn.1000-8179.2016.04.286
引用本文: 武海涛①, 姬忠贺①, 张倩①, 彭开文①, 李雁①②. 洛铂联合多西他赛行肿瘤细胞减灭术加腹腔热灌注化疗治疗同时性胃癌腹膜癌*[J]. 中国肿瘤临床, 2016, 43(4): 146-151. DOI: 10.3969/j.issn.1000-8179.2016.04.286
shu
Haitao WU1, Zhonghe JI1, Qian ZHANG1, Kaiwen PENG1, Yan LI1. Treatment of synchronous peritoneal carcinomatosis from gastric cancer with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2016, 43(4): 146-151. DOI: 10.3969/j.issn.1000-8179.2016.04.286
Citation: Haitao WU1, Zhonghe JI1, Qian ZHANG1, Kaiwen PENG1, Yan LI1. Treatment of synchronous peritoneal carcinomatosis from gastric cancer with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2016, 43(4): 146-151. DOI: 10.3969/j.issn.1000-8179.2016.04.286
shu

洛铂联合多西他赛行肿瘤细胞减灭术加腹腔热灌注化疗治疗同时性胃癌腹膜癌*

Treatment of synchronous peritoneal carcinomatosis from gastric cancer with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel

    摘要
  • 摘要: 目的：分析洛铂联合多西他赛行肿瘤细胞减灭术（cytoreductive surgery，CRS ）加腹腔热灌注化疗（hyperthermic intraperitoneal chemotherapy ，HIPEC）治疗同时性胃癌腹膜癌（peritoneal carcinoma，PC）的疗效及安全性。方法：50例胃癌PC患者接受52次CRS+HIPEC治疗，药物为洛铂100 mg、多西他赛120 mg，加入12000 mL生理盐水加热至（43± 0.5）℃ 持续灌注60min。主要终点指标为总生存期，次要终点评价指标为围手术期安全性。结果：患者中位随访期22.5 个月，中位生存期14.3 个月（95%CI：7.6～21.0），1、2、3 年生存率分别为58% 、40% 、32% 。无围手术期死亡，12例（23.1%）出现严重不良事件。多因素分析显示，完全细胞减灭、术前肿瘤标记物水平正常、术后化疗≥ 6 个周期为影响预后的独立因素。结论：对于同时性胃癌PC患者，洛铂联合多西他赛行CRS+HIPEC可延长患者的总生存期，安全可行。

     

    Abstract: Objective:To evaluate the efficacy and safety of combined cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) with lobaplatin and docetaxel for treatment of synchronous peritoneal carcinomatosis (PC) from gastric cancer. Methods:Fifty patients with synchronous PC from gastric cancer were treated by 52CRS+HIPEC procedures with 100 mg of lobaplatin and 120 mg of docetaxel in 12000 mL of normal saline at ( 43± 0. 5)℃ for 60min. The primary and secondary endpoints were overall survival (OS) and perioperative safety profiles, respectively. Results: At a median follow- up of 22. 5 months, the median OS rate was 14. 3 (95% CI:7. 6- 21. 0) months, and the 1- , 2- , and 3- year survival rates were 58% ,40% , and 32% , respectively. No perioperative deaths or serious adverse events occurred in12cases ( 23. 1%). Multivariate analysis indicated that completeness of cytoreduction, nor-mality of perioperative tumor markers, and adjuvant chemotherapy of more than six cycles were independent predictors for improved survival. Conclusions:CRS+HIPEC with lobaplatin and docetaxel could improve the OS and ensure perioperative safety of patients with synchronous PC from gastric cancer.

     

    • HTML全文
    • 参考文献(0)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回